PDF) High-dose interleukin-2 (HD IL-2) for advanced melanoma: A single center experience from the University of Pittsburgh Cancer Institute
High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort - ScienceDirect
Stable disease after high dose interleukin-2... | Posters | F1000Research
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer | Journal of Clinical Oncology
Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis | Rheumatology and Therapy
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute | Journal for ImmunoTherapy of Cancer
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 | Journal for ImmunoTherapy of Cancer
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism | Nature Communications
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases | Nature Reviews Immunology
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases - eBioMedicine
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute | Journal for ImmunoTherapy of Cancer | Full Text
Deciphering High-Dose IL-2 Toxicity in Reconstituted HIS Mice | genOway
Deciphering High-Dose IL-2 Toxicity in Reconstituted HIS Mice | genOway
Cancer Immunotherapy with Interleukin-2— Current Status and Future Developments | touchONCOLOGY
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 | Journal for ImmunoTherapy of Cancer
Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers: Molecular Therapy
Low-dose IL-2 found effective in SLE | MDedge Rheumatology
High dose interleukin-2 vs/or low dose interleukin-2 in advanced RCC | Download Table
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases | Nature Reviews Immunology
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control | Nature Communications
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer | Journal of Clinical Oncology
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial - The Lancet Rheumatology
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute | Journal for ImmunoTherapy of Cancer | Full Text
An Adaptive Control Scheme for Interleukin-2 Therapy - ScienceDirect
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition | Journal for ImmunoTherapy of Cancer | Full Text
Therapeutic potential of interleukin-2 in autoimmune diseases: Trends in Molecular Medicine
Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes | Nature Communications
![PDF] The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1f23201e3a6edfc28d3fbdee27850056503063a0/5-Table2-1.png "PDF] The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma | Semantic Scholar")
PDF] The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma | Semantic Scholar
Ongoing clinical trials using high-dose interleukin-2 | Download Table
